Dr. Matthew Keating, MD

Dr. Keating practices at UCI Health - Orange in Orange, California, part of UC Irvine.

Dr. Keating's NPI, 1275948481, was assigned on June 25, 2014. Dr. Keating graduated from Keck School of Medicine of USC in 2014. Dr. Keating's California license number on file is A139205.

Dr. Keating's primary practice is UCI Health - Orange, at 101 City Drive South, Orange, CA 92868 in Orange County. The practice phone is (714) 456-7890.

Dr. Keating's primary practice is UCI Health - Orange in Orange, California, part of UC Irvine. The medical group on file is UCI Health Physicians. Dmand AI also links Dr. Keating to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Keating practices, 2 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Keating's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Keating is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Keating's licenses on file in 3 states: California, Massachusetts and Rhode Island.

Dmand AI lists arterial blot clot /embolism, breast cancer, chronic anemia, chronic embolism thrombosis, colorectal cancer, deep vein thrombosis (DVT), immune deficiency disease and lung cancer among the conditions Dr. Keating treats.

CMS data shows 947 Medicare services from Dr. Keating across 3 procedure codes in 2024, for 369 Medicare patients. Medicare paid $144,998 for them. Every service was in an office.

CMS counts 369 Medicare patients who saw Dr. Keating in 2024. The largest group is 65 to 74, with 158 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 28% are also on Medicaid. Their average risk score is 2.19, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Keating's median patient age at 59, with 65% women.

In 2024, Dr. Keating wrote 552 Medicare Part D claims for 113 patients. 66% of them were for generic drugs. CMS names the drug for 342 of them, across 15 drugs with 11 or more claims each, at $904,070 in total drug cost. In 2023, CMS named 238 claims across 9 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Keating for performance year 2024, reported through an alternative payment model (APM). Dr. Keating accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Keating as offering telehealth.

Dmand AI links 16 papers to Dr. Keating, published from 2016 to 2023. 2021 was the busiest year, with 8. The most frequent topics are Antineoplastic Agents and Machine Learning. Dr. Keating has published most often in Cureus. Dr. Keating's most frequent co-authors are Toufic Tannous, MD, Constantin Dasanu, MD, PhD and Andrew Wei Chong Mak, MD.

CMS Open Payments shows 24 general payments to Dr. Keating from 12 drug and device companies from 2017 to 2024. Food and beverage make up the largest share, 95% of the total. Janssen Pharmaceuticals, Inc paid the most, $577.

Dr. Keating graduated from Keck School of Medicine of USC in 2014.

Dr. Keating is in network with 13 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.